文献速递前列腺癌

前列腺癌伴骨转移男性的减瘤性根治性前列腺切除术

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
PubMed 文献 · Eur Urol Oncol · 2018-05-15

这项回顾性多中心研究纳入113例经活检证实的前列腺癌伴骨转移(mPCA)患者,评估减瘤性根治性前列腺切除术(CRP)的肿瘤学和功能结局。3年和5年总生存率分别为87.6%和79.6%,Clavien-Dindo IIIa-b级并发症发生率为9.7%。作者认为CRP可能是个体化治疗选择,但应在临床方案框架内进行,不代表标准治疗选择。

要点

  • 113例mPCA患者行CRP后3年和5年总生存率分别为87.6%和79.6%。
  • Clavien-Dindo IIIa-b级并发症发生率为9.7%,无、轻度、重度尿失禁分别为68.1%、17.7%、14.1%。
  • 作者认为CRP可能是个体化治疗选择,应在临床方案框架内进行,不代表标准治疗选择。

核心结论

  • CRP在经过良好选择的患者中5年总生存率为80%,显著并发症发生率低,功能结局良好。
  • CRP可能成为mPCA多模式管理中的个体化治疗选择。
  • CRP应在临床方案框架内进行,不代表标准治疗选择。

研究设计与样本

  • 回顾性、多中心研究,纳入113例经活检证实的前列腺癌伴骨转移(mPCA)患者。
  • 入选标准包括:完全可切除的前列腺癌、骨转移、无腹膜后淋巴结大体转移、无>3cm的盆腔淋巴结大体转移、无或轻微内脏转移、ECOG体能状态评分0-1、书面知情同意。
  • 干预为CRP联合扩大盆腔淋巴结清扫;80例(70.8%)接受新辅助ADT,91例(86.5%)接受辅助ADT和/或放疗。

主要发现

  • 患者平均年龄61岁(范围42-69),平均随访53.6个月(范围13-96,中位45.7)。
  • 3年和5年总生存率分别为87.6%和79.6%,平均临床无复发生存期(CRFS)为72.3个月。
  • 术前PSA<1.0ng/ml和PSA低于中位数8.0ng/ml与生化无复发生存期(BRFS)显著相关(p<0.0004)。
  • 病理组织学显示所有病例均有存活前列腺癌:pT4a 16例(14.2%)、pT2a-c 21例(18.6%)、pT3a/b 76例(67.3%);淋巴结阳性61.6%,手术切缘阳性36.8%。
  • 11例(9.7%)发生Clavien-Dindo IIIa-b级并发症;低体积疾病、新辅助ADT和术前PSA与手术相关并发症风险降低显著相关(p<0.05)。

临床怎么用

  • 作者认为CRP可能成为mPCA多模式管理中的个体化治疗选择。
  • 作者指出CRP应在临床方案框架内进行,不代表标准治疗选择。

局限性

  • 研究局限性为回顾性性质。
  • 研究局限性为潜在的患者选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Androgen deprivation therapy (ADT) represents the standard treatment for hormone-naïve prostate cancer with systemic metastases (mPCA). The role of radical prostatectomy (RP) in this setting is unclear. OBJECTIVE: To evaluate the oncological and functional outcomes of men with mPCA who underwent cytoreductive RP (CRP). DESIGN, SETTING, AND PARTICIPANTS: Retrospective, multi-institutional study of 113 patients with biopsy-proven mPCA who fulfilled the following selection criteria: (1) completely resectable PCA; (2) osseous metastases; (3) absence of gross retroperitoneal lymph node metastases; (4) absence of bulky pelvic lymph node metastases >3cm; (5) no or minimal visceral metastases; (6) Eastern Cooperative Oncology Group performance status of 0-1; and (7) written informed consent. INTERVENTION: CRP with extended pelvic lymphadenectomy. Eighty patients (70.8%) received neoadjuvant ADT and 91 (86.5%) adjuvant ADT and/or radiation therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cancer-specific survival, overall survival (OS), biochemical relapse-free survival (BRFS), and clinical relapse-free survival (CRFS) were evaluated using descriptive statistical analyses, the Kaplan-Meier method, and univariate and multivariate analyses. Treatment-associated complications were analysed according to the Clavien-Dindo classification. RESULTS AND LIMITATIONS: The mean patient age was 61 yr (range 42-69). The mean follow-up was 53.6 mo (range 13-96, median 45.7). The 3-yr and 5-yr OS was 99 (87.6%) and 90 (79.6%), respectively, and the mean CRFS was 72.3 mo. Preoperative prostate-specific antigen (PSA)<1.0ng/ml and PSA below the median of 8.0ng/ml were significantly associated with BRFS (p<0.0004). Pathohistology revealed viable PCA in all cases: 16 (14.2%) had pT4a, 21 (18.6%) had pT2a-c, and 76 (67.3%) had pT3a/b PCA. Positive lymph nodes were identified in 61.6% and positive surgical margins in 36.8% of the patients. Eleven men (9.7%) experienced Clavien Dindo grade IIIa-b complications. Low-volume disease, neoadjuvant ADT, and preoperative PSA were significantly associated with a lower risk of surgery-related complications (p<0.05). No, mild (1-2 pads/d), and severe incontinence (>2 pads/d) was observed in 68.1%, 17.7%, and 14.1%, respectively. Limitations of the study are the retrospective nature and potential patient selection bias. CONCLUSIONS: CRP results in 5-yr OS of 80%, a low rate of significant complications, and good functional outcome in well-selected patients. CRP might be an individualised treatment option in the multimodal management of mPCA. PATIENT SUMMARY: We assessed oncological and functional outcomes associated with cytoreductive radical prostatectomy (CRP) in select men with prostate cancer and osseous metastases. We found that CRP might be associated with long overall and relapse-free survival in well-selected patients. CRP could become an additional treatment option in the multimodal therapy of metastatic prostate cancer; it should be performed in a clinical protocol setting and does not represent a standard therapeutic option.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Heidenreich A, Fossati N, Pfister D, et al. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. Eur Urol Oncol. 2018. PMID: 31100228. doi:10.1016/j.euo.2018.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。